on GENOWAY (EPA:ALGEN)
GenOway Announces the Publication of its 2025 Annual Revenue
On January 19, 2026, genOway, a specialist in predictive preclinical solutions, announced that its 2025 annual revenue will be published on January 26, 2026, after the close of Euronext markets. Listed on Euronext Growth, genOway contributes to the safe and efficient selection of drug candidates by its clients.
On this occasion, a webinar will be held at 6:15 p.m. for shareholders and individual investors. Alexandre Fraichard, CEO, will discuss the company's activities for 2025 and its strategic outlook. This outlook is strengthened by the recent acquisition of assets in OMICS and artificial intelligence.
Registration for the webinar is open until the day of the event. Registered participants will receive instructions on how to participate. Questions can be sent to genoway@actus.fr.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENOWAY news